HIV Latency Gets a New Histone Mark.
Bryan C. Nikolai,Qin Feng
DOI: https://doi.org/10.1016/j.chom.2017.04.012
IF: 31.316
2017-01-01
Cell Host & Microbe
Abstract:Transcriptional latency of integrated HIV-1 provirus represents a major obstacle to curing HIV. In this issue of Cell Host & Microbe, Boehm et al., 2017Boehm D. Jeng M. Camus G. Gramatica A. Schwarzer R. Johnson J.R. Hull P.A. Montano M. Sakane N. Pagans S. et al.Cell Host Microbe. 2017; 21 (this issue): 569-579Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar identify a new lysine methyltransferase that writes a repressive histone mark associated with HIV-1 latency. The results are important for strategies to pharmacologically reverse HIV-1 latency. Transcriptional latency of integrated HIV-1 provirus represents a major obstacle to curing HIV. In this issue of Cell Host & Microbe, Boehm et al., 2017Boehm D. Jeng M. Camus G. Gramatica A. Schwarzer R. Johnson J.R. Hull P.A. Montano M. Sakane N. Pagans S. et al.Cell Host Microbe. 2017; 21 (this issue): 569-579Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar identify a new lysine methyltransferase that writes a repressive histone mark associated with HIV-1 latency. The results are important for strategies to pharmacologically reverse HIV-1 latency. The success of anti-retroviral (ARV) therapy has led to a drastic reduction in the number of people dying of AIDS, but the spread and persistence of human immunodeficiency virus 1 (HIV-1) continues to be problematic (Martin and Siliciano, 2016Martin A.R. Siliciano R.F. Annu. Rev. Med. 2016; 67: 215-228Crossref PubMed Scopus (61) Google Scholar). HIV genomes can lay hidden for decades under ARV therapy before reemerging in a manifest of viral load symptoms, leading to eventual relapse of AIDS upon treatment withdrawal. Consequently, despite over 30 years of medical advancement toward controlling viral replication and preventing AIDS, transcriptional latency represents a major barrier to curing HIV (Margolis et al., 2016Margolis D.M. Garcia J.V. Hazuda D.J. Haynes B.F. Science. 2016; 353: aaf6517Crossref PubMed Scopus (163) Google Scholar). Moreover, ARV treatment is not without consequence. Patients taking ARVs can experience debilitating comorbidities, and the viral load can rebound upon drug withdrawal (Gutierrez and Balasubramanyam, 2012Gutierrez A.D. Balasubramanyam A. Endocrine. 2012; 41: 1-10Crossref PubMed Scopus (61) Google Scholar). Recent evidence indicates that entry into and release from proviral transcriptional latency are epigenetic events amenable to pharmacological targeting, with potential for viral eradication using so-called shock and kill strategies. In eukaryotic cells, each nucleosome contains two subunits of each core histone: H2A, H2B, H3, and H4, with DNA packaged by wrapping approximately twice around each histone octamer. This basic nucleosomal unit is repeated across the entire genome and provides an intricate structural complexity for precise regulation of gene expression in response to cellular signaling. Key to this regulation are post-translational modifications (PTMs) of histone tails, including phosphorylation, methylation, acetylation, crotonylation, and ubiquitination, among many others. Upon integration into the host cell genome, proviral HIV-1 DNA is organized into defined nucleosome structures, and viral transcription is obligated on cellular chromatin remodeling events. Similar to the transcriptional regulation of cellular genes, HIV-1 transcription is epigenetically regulated by coregulator chromatin modifiers, including “writers,” “readers,” and “erasers” (Figure 1). For instance, HIV-1 proviral activity is associated with transcriptionally active modifications such as histone acetylation, H3K4 trimethylation (H3K4me3), and H3K36 trimethylation (H3K36me3) (Yoh et al., 2008Yoh S.M. Lucas J.S. Jones K.A. Genes Dev. 2008; 22: 3422-3434Crossref PubMed Scopus (171) Google Scholar, Le Douce et al., 2012Le Douce V. Colin L. Redel L. Cherrier T. Herbein G. Aunis D. Rohr O. Van Lint C. Schwartz C. Nucleic Acids Res. 2012; 40: 1904-1915Crossref PubMed Scopus (58) Google Scholar). Conversely, histone PTMs associated with repressive chromatin are deposited at HIV regulatory sequences upon latency. Removal of histone acetylation is mediated by various histone deacetylase enzymes (HDACs). Inhibition of HDACs can reverse latency, although this alone is insufficient to have significant clinical value (Margolis et al., 2016Margolis D.M. Garcia J.V. Hazuda D.J. Haynes B.F. Science. 2016; 353: aaf6517Crossref PubMed Scopus (163) Google Scholar). Recently, evidence has emerged for a critical role of lysine methyltransferases (KMTs) during induction and maintenance of latent HIV-1 provirus (Nguyen et al., 2017Nguyen K. Das B. Dobrowolski C. Karn J. MBio. 2017; 8 (e00133-17)Crossref Scopus (83) Google Scholar). In contrast to lysine methyl marks associated with active transcription, such as H3K4me3 and H3K36me3 mentioned above, methylation of H3K27 or H3K9 by the KMTs EZH2, G9a, or SUV39H1 promotes entry into latency through formation of repressive chromatin (Nguyen et al., 2017Nguyen K. Das B. Dobrowolski C. Karn J. MBio. 2017; 8 (e00133-17)Crossref Scopus (83) Google Scholar, Marban et al., 2007Marban C. Suzanne S. Dequiedt F. de Walque S. Redel L. Van Lint C. Aunis D. Rohr O. EMBO J. 2007; 26: 412-423Crossref PubMed Scopus (286) Google Scholar, du Chéné et al., 2007du Chéné I. Basyuk E. Lin Y.L. Triboulet R. Knezevich A. Chable-Bessia C. Mettling C. Baillat V. Reynes J. Corbeau P. et al.EMBO J. 2007; 26: 424-435Crossref PubMed Scopus (254) Google Scholar). Now, Boehm and colleagues describe a new histone modification and the writer/reader pair of host coregulator proteins responsible for a latency switch of HIV transcription (Figure 1). In this issue of Cell Host & Microbe, Boehm et al., 2017Boehm D. Jeng M. Camus G. Gramatica A. Schwarzer R. Johnson J.R. Hull P.A. Montano M. Sakane N. Pagans S. et al.Cell Host Microbe. 2017; 21 (this issue): 569-579Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar report on an RNAi screen to query KMTs involved in HIV latency reversal and identify SMYD2, a member of a family of non-canonical SET-domain-containing chromatin modifiers, as an HIV provirus corepressor. Knockdown of SMYD2 relieves HIV latency in model reporter cell lines, and the bioavailable SMYD2 inhibitor AZ391 increases cellular transcript levels of HIV in CD4+ T cells from patients with suppressed viral load. The authors demonstrate recruitment of SMYD2 to the HIV promoter by chromatin immunoprecipitation (ChIP) under latency conditions, and dismissal of SMYD2 upon TNFα stimulation and latency reversal. Importantly, using various biochemical assays, SMYD2 is identified as a key enzyme for H4K20 monomethylation, a histone mark previously not attributed to this enzyme and unrecognized to play a role in HIV proviral latency. Indeed, H4K20me1 is detected by ChIP at the HIV promoter region in latent cells, but decreased upon latency reversal or SMYD2 knockdown while H4K20 di- and tri-methylation levels are unchanged. The H4K20me1 mark is known to recruit a chromatin reader protein named L3MBTL1, which plays a role in heterochromatin formation. SMYD2 knockdown or TNFα treatment precluded L3MBTL1 occupancy at the HIV promoter, suggesting that monomethylation of H4K20 by SMYD2 is a critical mechanism of proviral transcriptional latency (Boehm et al., 2017Boehm D. Jeng M. Camus G. Gramatica A. Schwarzer R. Johnson J.R. Hull P.A. Montano M. Sakane N. Pagans S. et al.Cell Host Microbe. 2017; 21 (this issue): 569-579Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar). Therefore, inhibitors of SMYD2 such as AZ391 may represent a new class of latency-reversing agents (LRAs). A curious observation from this study is the absence of synergy or even additive effects with other LRAs, including the bromodomain inhibitor JQ1, which has been postulated to function as an LRA by reducing competition for Tat with P-TEFb (Zhu et al., 2012Zhu J. Gaiha G.D. John S.P. Pertel T. Chin C.R. Gao G. Qu H. Walker B.D. Elledge S.J. Brass A.L. Cell Rep. 2012; 2: 807-816Abstract Full Text Full Text PDF PubMed Scopus (186) Google Scholar). Since the authors suggest that SMYD2 repression of HIV transcription is independent of Tat, it is somewhat surprising that this additional treatment would not further stimulate reversal of HIV-1 transcriptional latency. Despite the elegant mechanistic work described in this paper, the lack of combinatorial effects of AZ391 with other LRAs underscores a deficit of knowledge about how coregulators like SMYD2 function, together with L3MBTL1, to maintain HIV latency. The observation that levels of SMYD2 transcript are reduced upon JQ1 treatment may partially explain the paucity of additive effects, but it also suggests important nuances that are required to be considered in combination therapies targeting multiple pathways of latency reversal. Further research into coregulator mechanisms of epigenetic-mediated HIV-1 latency and proviral transcription should lead to deeper understanding of actionable targets for overcoming HIV-1 persistence. SMYD2-Mediated Histone Methylation Contributes to HIV-1 LatencyBoehm et al.Cell Host & MicrobeMay 10, 2017In BriefTranscriptional latency of HIV is a last barrier to viral eradication. Boehm et al. identify the lysine methyltransferase SMYD2 as a regulator of HIV-1 latency via histone H4K20me1 methylation at the HIV LTR. Pharmacological SMYD2 inhibitors reactivate latent HIV-1 in primary T cells, suggesting a strategy for therapeutic latency reversal. Full-Text PDF Open Archive